Boehringer Ingelheim Achieves Strong Financial Performance with Strategic Drug Launches in 2025
Boehringer Ingelheim has reported a successful year in 2025, marked by significant financial growth and the strategic launch of two important medications in its Human Pharma division. The global pharmaceutical company demonstrated resilience and innovation throughout the challenging market conditions of the year.
Impressive Financial Results and Research Commitment
The company's group net sales increased by 7.3% to €27.8 billion for the full year 2025, supported by strong performances across both Human Pharma and Animal Health business segments. This growth reflects the company's strategic focus on delivering innovative healthcare solutions to patients worldwide.
Research and Development investments reached €6.4 billion in 2025, representing 22.9% of group net sales. This substantial commitment to innovation underscores Boehringer Ingelheim's dedication to advancing medical science and developing new treatments for critical health conditions.
Breakthrough Therapies Reach Patients
In the second half of 2025, Boehringer Ingelheim successfully launched two medicines that had received FDA Breakthrough Therapy designation:
- HERNEXEOS® (zongertinib): An oral treatment for HER2-mutant advanced non-small cell lung cancer, launched in the United States in August 2025
- JASCAYD® (nerandomilast): Approved in both the United States and China for idiopathic pulmonary fibrosis (IPF) in October 2025, with additional approval for progressive pulmonary fibrosis (PPF) in December 2025
These launches represent significant advancements in treating serious lung conditions, with JASCAYD® marking the first new innovative therapy for IPF to reach the market in over a decade.
Human Pharma Division Shows Robust Growth
The Human Pharma business unit reported sales growth of 7.4% to €22.7 billion, driven by strong performance from established brands and the introduction of new therapies. Key products contributing to this success include:
- JARDIANCE® (empagliflozin): Grew 8.7% to €8.8 billion, treating chronic kidney disease, type 2 diabetes, and heart failure
- OFEV® (nintedanib): Increased 5.4% to €3.8 billion, used for idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases
The Human Pharma division invested €5.8 billion in R&D, equivalent to 27.4% of the unit's net sales, demonstrating a strong commitment to future innovation.
Leadership Perspective on Strategic Direction
Shashank Deshpande, Chairman of the Board of Managing Directors responsible for Human Pharma, commented on the company's achievements: "2025 reinforced the strength of our pipeline and underscored the impact of our long-term investment in R&D. With two newly launched medicines in oncology and respiratory, we are addressing high unmet medical needs of patients, while also driving the renewal of our portfolio."
Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: "In volatile markets and amid regional challenges, our business proved resilient as we focused on what we do best: bringing more medicines to patients and animals. We are investing more than ever in innovation, which reflects our ambition for the next years."
Expanding Patient Reach and Pipeline Development
Boehringer Ingelheim reached 70 million patients in 2025, an increase from 66 million in 2024, demonstrating the company's growing impact on global healthcare. The company's pipeline continues to expand, now including more than 80 projects representing over 50 new molecular entities across multiple therapeutic areas:
- Cardiovascular, renal and metabolic diseases (CRM)
- Oncology
- Respiratory and immunology
- Mental health
- Eye health
The company's growing mid- and late-stage pipeline positions Boehringer Ingelheim for sustained future growth and continued delivery of transformative treatments to patients worldwide. As 2026 progresses, the company anticipates pivotal Phase III programs, important clinical readouts, and additional new launches that will further strengthen its position in the global pharmaceutical landscape.
